/
Oncology
Patients With Advanced Solid Tumors
250
Pipeline Programs↗
238
Active Trials↗
261
Companies Involved↗
Patients With Advanced Solid Tumors is a highly competitive landscape with 250 programs across 261 companies. The most active players are Qilu Pharmaceutical Co., Ltd., Jiangsu Hansoh Pharmaceutical Co., Ltd., Jacobio Pharmaceuticals Co., Ltd..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Qilu Pharmaceutical Co., Ltd.
8 programs
Jiangsu Hansoh Pharmaceutical Co., Ltd.
4 programs
Jacobio Pharmaceuticals Co., Ltd.
3 programs
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
3 programs
Shanghai Hengrui Pharmaceutical Co., Ltd.
3 programs
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
3 programs
Pipeline
Programs by Phase
Preclinical3
Phase 1119
Phase 2128
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
89%
Small molecule
205 of 231 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 231 classified programs, each share of the total. Modality classified for 100% of 250 pipeline programs.
Analysis
Trial Status
941
clinical trials
Completed440 · 47%
Recruiting160 · 17%
Unknown status142 · 15%
Terminated101 · 11%
Active, not recruiting41 · 4%
Not yet recruiting35 · 4%
Other22 · 2%
Clinical Trials
Trial Activity
941 trials
A Clinical Study of [177Lu]Lu-XT117 Injection in Patients With Advanced Solid Tumors
Recruiting·—·Phase 1·NCT06211647·20 enrolled
Page 1 of 63
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)